Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07127874 · ClinicalTrials.gov registry record · Phase 1
A Study of PHN-012 in Patients With Advanced Solid Tumors
A Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors, sponsored by Pheon Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 165
- Enrollment target
- 7
- Study locations
NCT07127874: Recruiting Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors, sponsored by Pheon Therapeutics.
NCT07127874 is a Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors that is actively recruiting participants, run by Pheon Therapeutics. The registered enrollment target is 165 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (58% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07127874, a Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors, is actively recruiting participants, sponsored by Pheon Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 165 participants
- Enrollment target
- 7
- Study locations
Study Summary
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG PHN-012
Study Locations (7)
Texas
- PHN-012-001 Site - Houston
- PHN-012-001 Site - San Antonio
District of Columbia
- PHN-012-001 Site - Washington D.C.
Massachusetts
- PHN-012-001 Site - Boston
North Carolina
- PHN-012-001 Site - Durham
Tennessee
- PHN-012-001 Site - Nashville
Virginia
- PHN-012-001 Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2025-09-23 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
What NCT07127874 shows while recruiting
NCT07127874 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (58% lower).
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which PHN-012 is the first listed.
NCT07127874 lists 7 locations in 6 states (Texas, District of Columbia, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT07127874 about?
NCT07127874 is a clinical study titled "A Study of PHN-012 in Patients With Advanced Solid Tumors". This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
What is the current status of trial NCT07127874?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 165 participants. The study started on 2025-09-23. Estimated completion is 2028-05.
What conditions does trial NCT07127874 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Advanced Solid Tumors, Advanced Cancer, Colon Cancer, Lung Cancer (NSCLC).
What interventions are being tested in trial NCT07127874?
The interventions under investigation include: PHN-012 (DRUG).
Who is sponsoring clinical trial NCT07127874?
This trial is sponsored by Pheon Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07127874 being conducted?
This trial has 7 study locations across District of Columbia, Massachusetts, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07127874's enrollment target sits among peer trials
165 75th of 278 higher than 204 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI